JANSSEN® CONNECT™
provides resources and support when you prescribe
INVEGA® SUSTENNA® (paliperidone palmitate) and RISPERDAL® CONSTA® (risperidone).
provides resources and support when you prescribe
INVEGA® SUSTENNA® (paliperidone palmitate) and RISPERDAL® CONSTA® (risperidone).

Disclaimer: Reimbursement-support services and care-coordination services (e.g., referral to alternate sites of care, appointment scheduling and reminders, prescription delivery coordination) are provided as a service by United BioSource Corporation (“UBC”), under contract for Janssen Pharmaceuticals, Inc. (“JPI”).
A Patient Enrollment Form (PEF), with sections completed for coordination of alternate sites of care, injection coordination, benefit investigation, outpatient transition support, reminder calls, patient education, and/or other support services, must be submitted to UBC by the prescriber in order to activate any JANSSEN® CONNECT™ services. No other forms for request of JANSSEN® CONNECT™ services will be accepted. Services cannot be directly requested by the patient. JANSSEN® CONNECT™ care coordination is not available to patients participating in a Patient Assistance Program (PAP). Certain restrictions on program availability may apply.
UBC assists healthcare professionals in the determination of whether treatment could be covered by the applicable third-party payer, based on coverage guidelines provided by the payer and patient information provided by the healthcare provider under appropriate authorization following the provider’s exclusive determination of medical necessity. These support services are made available as a convenience to patients, and no additional compensation is required from or paid to patients or prescribers as part of their delivery. Importantly, insurance verification is the ultimate responsibility of the provider. Third-party reimbursement is affected by many factors. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. Similarly, all CPT* and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee expressed or implied by JPI or UBC that these codes will be appropriate or that reimbursement will be made. The fact that a drug, device, procedure, or service is assigned an HCPCS code and a payment rate does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. Fiscal Intermediaries (FIs)/Medicare Administrative Contractors (MACs) and/or State Medicaid program administration determine whether a drug, device, procedure, or other service meets all program requirements for coverage.1,2 It is not intended to increase or maximize reimbursement by any payer.
Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While JPI and UBC have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. JPI and UBC strongly recommend you consult the payer organization for its reimbursement policies. While UBC tries to provide correct information, they and JPI make no representations or warranties, expressed or implied, as to the accuracy of the information. In no event shall UBC or JPI, or their employees or agents, be liable for any damages resulting from or relating to the services. All providers and other users of this information agree that they accept responsibility for the use of this service.
JPI assumes no responsibility for, and does not guarantee the quality, scope, or availability of the services including, but not limited to, injection coordination, benefit investigation, outpatient transition support, reminder calls, patient education, and other support services. Each provider, not JPI, is responsible for the services they provide.
* CPT – Current Procedural Terminology, copyright of the American Medical Association, 2011.
References: 1. Centers for Medicare & Medicaid Services. CMS Manual System, Pub 100-04 Medicare Claims Processing.
http://www.cms.gov/transmittals/downloads/R1139CP.pdf. Accessed October 20, 2011.
2. 2011 HCPCS Level II Professional Edition, American Medical Association, 2010. (Pg. 84).
INVEGA® SUSTENNA® (paliperidone palmitate) extended-release injectable suspension is indicated for the acute and maintenance treatment of schizophrenia in adults.
IMPORTANT SAFETY INFORMATION FOR INVEGA® SUSTENNA® (paliperidone palmitate)
WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drugtreated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® SUSTENNA® is not approved for the treatment of patients with dementia-related psychosis.
RISPERDAL® CONSTA® (risperidone) long-acting injection is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder and for the treatment of schizophrenia.
IMPORTANT SAFETY INFORMATION FOR RISPERDAL® CONSTA® (risperidone)
WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis.
© Janssen Pharmaceuticals, Inc. 2011. All rights reserved.
Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.
This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This information is intended for the use of our healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.
Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc.
Some documents on this site are stored in Adobe PDF format and require the free Adobe® Reader® to view.
This page was last modified on:
EDT